Pralatrexate: basic understanding and clinical development (Q37761372)

22 August 2017

1 reference

title

Pralatrexate: basic understanding and clinical development (English)

1 reference

22 August 2017

1 reference

2

Owen O'Connor

1 reference

22 August 2017

Jasmine Zain

1

1 reference

PubMed ID

20509772

22 August 2017

language of work or name

English

0 references

publication date

1 July 2010

1 reference

Expert Opinion on Pharmacotherapy

22 August 2017

1 reference

22 August 2017

11

1 reference

22 August 2017

10

1 reference

22 August 2017

1705-1714

1 reference

Human reduced folate carrier: translation of basic biology to cancer etiology and therapy

22 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489552

The human reduced folate carrier gene is regulated by the AP2 and sp1 transcription factor families and a functional 61-base pair polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489552

Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489552

Carrier-mediated membrane transport of folates in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489552

Synthesis and antitumor activity of 10-propargyl-10-deazaaminopterin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489552

Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489552

Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489552

Pralatrexate: an emerging new agent with activity in T-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489552

A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489552

Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patients with unresectable malignant pleural mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489552

Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489552

The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting--Airlie House, Virginia, November, 1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489552

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489552

The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489552

A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489552

A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.489552

10.1517/14656566.2010.489552

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20509772